JPRN-jRCTs041180174进行中（未招募）2 期
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma - HL-14
Koga Yuhki0 个研究点目标入组 50 人开始时间: 2019年3月29日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 至 < 20age old（—）
- 性别
- All
入选标准
- •(1) diagnosis of Hodgkin's lymphoma
- •(2) age under 20 year old at diagnosis
- •(3) registration at JPLSG CHM-14 study
- •(4) written informed consent obtained from patient and/or guardians
排除标准
- •(1) Cases where impaired liver, kidney and cardiac functions compromise experimental treatment
- •(2) Patients who have been treated with anticancer drugs or radiation therapy
- •(3) Presence of CNS degenerative lesion
- •(4) Associated intracranial hemorrhage which hinders execution of treatment process
- •(5) Associated infection which is difficult to control
- •(6) Pregnant or possibility of pregnancy
- •(7) Women who are breastfeeding
- •(8) Past history of malignant neoplasm or multiple primary neoplasms
- •(9) History of congenital or acquired immune deficiency syndrome
- •(10) Any other reasons that the attending physician has deemed unsuitable
研究者
相似试验
招募中
2 期
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)s lymphomaHodgkin'JPRN-UMIN000019093Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)50
招募中
不适用
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 TherapyMetastatic MelanomaNCT03888950Centre Hospitalier Universitaire de Nice20
招募中
不适用
Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)Metastatic colorectal cancer receiving third-line therapy with cetuximabCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12612000052831Chang Gung Memorial Hospital30
已完成
2 期
A clinical trial to see whether outcomes in Hodgkins Lymphoma can be improved by using increased intensity therapy in interim PET scan positive patientsCTRI/2012/06/002741Cancer Institute50
进行中（未招募）
1 期
Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II studyAdvanced stage Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10020206Term: Hodgkin's diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10020243Term: Hodgkin's disease NECSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000498-35-PLEuropean Organisation for Research and Treatment of Cancer (EORTC)150